ArticleThe oncologist2021

Cost-Effectiveness of Pembrolizumab plus Axitinib Versus Sunitinib as First-Line Therapy in Advanced Renal Cell Carcinoma in the U.S.

Dong Ding et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.